Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 2,673 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo oral capsules Clear all
Completed Phase 2 Interventional

Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

NCT06331624
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, IPF
Interventions
Tazarotene (GRI-0621), Placebo
Drug
Lead sponsor
GRI Bio Operations, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Newport Beach, California • Jacksonville, Florida • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 18, 2026, 2:48 AM EDT
Recruiting Phase 3 Interventional

Pridopidine Phase 3 Study in Huntington's Disease

NCT07609108
View directory record Official record
Conditions
Huntington Disease
Interventions
Pridopidine, Placebo
Drug
Lead sponsor
Prilenia
Industry
Eligibility
23 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
25
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 2:48 AM EDT
Terminated Phase 3 Interventional

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)

NCT00658008
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
PD 0332334, Paroxetine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Litchfield Park, Arizona • Costa Mesa, California • Pasadena, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2012 · Synced Oct 18, 2026, 2:48 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Interactions of Cannabidiol (CBD) With Morphine

NCT05143424
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Morphine Sulfate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Trial of Roflumilast in Asthma Management (TRIM)

NCT03532490
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Roflumilast 500 Mcg Oral Tablet, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Tucson, Arizona • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)

NCT02534480
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
NGP 555
Drug
Lead sponsor
NeuroGenetic Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 18, 2026, 2:48 AM EDT
Recruiting Phase 2 Interventional

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

NCT07169279
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
0 Years to 32 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Oakland, California • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional

A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

NCT00135408
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Ipilimumab+ Placebo, Ipilimumab+ Budesonide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 18, 2026, 2:48 AM EDT
Active, not recruiting Phase 3 Interventional

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

NCT04333576
View directory record Official record
Conditions
Endometriosis
Interventions
Elagolix, Placebo, Combined Oral Contraceptive
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
176
States / cities
Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 134 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 18, 2026, 2:48 AM EDT
Terminated Phase 1 Interventional

A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism

NCT04209179
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
PCO371, Placebo
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Torrance, California • Chicago, Illinois • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and PK Study of EC-18 in Healthy Subjects

NCT02496143
View directory record Official record
Conditions
Chemotherapy-induced Neutropenia
Interventions
EC-18, Placebo
Drug
Lead sponsor
Enzychem Lifesciences Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Chronic Low Back Pain Research Project

NCT00108550
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
gabapentin, Inert placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

NCT02449018
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
QBW251, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Birmingham, Alabama • Fullerton, California • Waterbury, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

NCT02278120
View directory record Official record
Conditions
Advanced Metastatic Breast Cancer
Interventions
Ribociclib, Tamoxifen, Letrozole, Anastrozole, Goserelin, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 59 Years · Female only
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
35
States / cities
Bakersfield, California • Los Angeles, California • Denver, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Influence of Oral Probiotics on the Microbiome and Lipidome

NCT03605108
View directory record Official record
Conditions
Gut Microbiome, Skin Microbiome, Gut Lipidome, Skin Lipidome, Blood Lipidome
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pregabalin and Colonic Function

NCT01094808
View directory record Official record
Conditions
Healthy
Interventions
Pregabalin, Placebo, Bowel preparation
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Oct 18, 2026, 2:48 AM EDT
Withdrawn Phase 2 Interventional

90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

NCT01048086
View directory record Official record
Conditions
Neuroblastoma, Neuroendocrine Tumor
Interventions
Retinoic Acid, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
6 Months to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 18, 2026, 2:48 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19

NCT04474483
View directory record Official record
Conditions
COVID-19
Interventions
Melatonin, Placebo (Methylcellulose) capsule
Drug · Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Gut-brain Axis: a Novel Target for Treating Behavioral Alterations in Obesity

NCT01976156
View directory record Official record
Conditions
Neural Response in Caudate, Weight Loss Trial, Impulsivity
Interventions
PhosphoLean, Placebo
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 3 Interventional

PRC-063 in an ADULT Workplace Environment

NCT02225639
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
PRC-063 25 mg, Placebo, PRC-063 35 mg, PRC-063 45 mg, PRC-063 55 mg, PRC-063 70 mg, PRC-063 85 mg, PRC-063 100 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Newport Beach, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 18, 2026, 2:48 AM EDT
Terminated Phase 4 Interventional Results available

Low Pain Prediction in Cesarean Section Patients

NCT02143141
View directory record Official record
Conditions
Scheduled Cesarean Sections, Postoperative Pain Management, Side Effects
Interventions
duramorph, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 18, 2026, 2:48 AM EDT
Not listed Not applicable Interventional

Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors

NCT04592354
View directory record Official record
Conditions
Treatment of Fatigue After Resolution of COVID-19 Infection
Interventions
Oxaloacetate Medical Food/Dietary Supplement
Dietary Supplement
Lead sponsor
Terra Biological LLC
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects

NCT01250366
View directory record Official record
Conditions
HCV (Genotype 1)
Interventions
INX-08189, Placebo matching with INX-08189, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Los Angeles, California • Plymouth, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study of LY2886721 Single Doses in Healthy Subjects

NCT01133405
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY2886721, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 18, 2026, 2:48 AM EDT